REGULATED INFORMATION
JUNE 14, 2012
TiGenix receives transparency notifications
Leuven (Belgium) - June 14, 2012 - TiGenix NV (NYSE Euronext Brussels: TIG) announced today that it has received transparency notifications pursuant to the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.
TiGenix received, and has published on its website, the following transparency notifications:
1. Joint notification by Genetrix S.L., Genetrix Life Sciences A.B., CX EBIP Agreement S.L.U., Pilar Matji Tuduri, Miguelina Matji Tuduri, Manuel Matji Tuduri, María José Lafita Torres, María Ángeles Lafita Torres, Elena Lafita Torres, Lucía Lafita Torres, Alfredo Lafita Torres, Alfredo Lafita Pardo, Emilia Torres Rojas, Surfolk SL, Jorge Alemany Herrera, José Antonio Matji Tuduri, Nerel S.L., Ventech S.A., LSP III Management B.V., Ysios Capital Partners S.G.E.C.R., Biopartners Capital S.L.U., Navarra Iniciativas Empresariales S.A., Novartis AG, Novartis Bioventures Ltd., Eduardo Bravo Fernández de Araoz, Claudia D'Augusta, Dirk Büscher, Capital Riesgo de la Communidad de Madrid S.A. S.C., Antonio Vilá Casas, JV Risk Technologies S.L., Bankinter S.A., Bankinter Capital Riesgo I FCR, Commercial Cueto 92 S.L., Suro Capital S.A. S.C.R., Inversora Bico S.L., José Ignacio Guzmán Uribe, Adolfo Carvajal Isla, Florent Gros, Ana Maria Vidorreta Gonzaléz, Ignacio Alvarez-Rendueles Villar, Gonzalo Bravo Zabalgoitia, Ramón Carné, EFG International AG, A&G Global Sicav-Midleton Fund, Roche Holding AG and Roche Finanz AG.
These shareholders were acting in concert pursuant to a lock-up agreement entered into on 3 May 2011. On 27 January 2012, Genetrix Life Sciences A.B., which previously held 6.40% of the TiGenix shares (and together with its affiliated companies 8.49% of the TiGenix shares), crossed below the 5% threshold, to continue to hold only 4.98%.
The participations of the other shareholders remained unchanged.
2. Joint notification by the same shareholders as those listed under item 1 above, to notify the termination of their agreement to act in concert. On 26 April 2012, all lock-up commitments under the 3 May 2011 lock-up agreement expired completely (part of the lock-up commitments having already expired prior to 26 April 2012).
3. Individual notifications by the following companies regarding their shareholdings on 26 April 2012, the end date of the action in concert:
· Biopartners Capital SLU: 2,977,440 shares (3.25%),
· Genetrix SL / Genetrix Life Sciences A.B. / CX EBIP Agreement SLU: 6,439,974 shares (5.69%),
· LSP III Management BV : 4,445,053 shares (4.85%),
· Novartis AG / Novartis Bioventures Ltd: 5,534,905 shares (6.04%),
· Roche Holding AG / Roche Finanz AG: 5,534,905 shares (6.04%),
· Ventech SA: 5,195,199 shares (5.67%), and
· Ysios Capital Partners SGECR: 4,760,342 shares (5.19%).
4. Notification by the companies Genetrix SL / Genetrix Life Sciences A.B. / CX EBIP Agreement SLU, following the crossing below the 3% threshold on 5 June 2012 by Genetrix Life Sciences A.B., after which the participations of these companies were as follows:
· Genetrix SL: no shares (0%),
· Genetrix Life Sciences A.B.: 2,686,867 shares (2.93%),
· CX EBIP Agreement SLU: 1,905,144 shares (2.08%),
· Total: 4,592,011 shares (5.01%).
5. Notification by the companies Genetrix SL / Genetrix Life Sciences A.B. / CX EBIP Agreement SLU, following the crossing below the 5% threshold on 7 June 2012 by the group as a whole, after which the participations of these companies were as follows:
· Genetrix SL: no shares (0%),
· Genetrix Life Sciences A.B.: 2,581,501 shares (2.82%),
· CX EBIP Agreement SLU: 1,905,144 shares (2.08%),
· Total: 4,486,645 shares (4.89%).
The chain of controlled undertakings through which the holdings are effectively held, is as follows: Genetrix S.L. controls Genetrix Life Sciences A.B. en Genetrix Life Sciences A.B. controls CX EBIP Agreement S.L.U.; Bankinter S.A. controls Bankinter Riesgo Capital I, FC.R.; Antonio Vila Casas controls JV Risk Technologies S.L.; José Antonio Matji Tuduri controls Nerel S.L.; A&G Global Sicav - Middleton Fund is controlled by A&G Global GP S.a.r.l. (Luxembourg),which is controlled by Asesores y Gestores Financieros S.A. (Spain), which is controlled by EFG Investment S.A. (Luxembourg), which is finally controlled by EFG International AG (Switzerland); Novartis AG controls Novartis Bioventures Ltd.; Commercial Cueto 92 S.L. controls Suro Capital S.A. S.C.R.; Roche Holding AG controls Roche Finanz AG; Surfolk SL is controlled by Maria José Lafita Torres, Ángeles Lafita Torres, Alfredo Lafita Torres, Elena Lafita Torres, Lucia Lafita Torres, Alfredo Lafita Pardo and Emilia Torres Rojas. The following legal persons are not controlled by another legal or natural person: Genetrix S.L., Ventech S.A., LSP III Management B.V., Ysios Capital Partners S.G.E.C.R., Biopartners Captial S.L.U., Navarra Iniciativas Empresariales S.A., Novartis AG, Bankinter S.A., Capital Riesgo de la Communidad de Madrid S.A. S.C., Commercial Cueto 92 S.L., Inversora BICO S.L., EFG International AG and Roche Holding AG.
For further details regarding these notifications, we refer to our website: http://www.tigenix.com/en/page/26/shareholders.
For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com
Hans Herklots
Director Investor & Media Relations
hans.herklots@tigenix.com
+32 16 39 60 97
About TiGenix
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with one marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.